Ozempic Public Funding Approval in Portugal: Key Insights and Implications

By HEOR Staff Writer

February 3, 2026

Ozempic public funding is now approved in Portugal for specific adults with type 2 diabetes. Infarmed's recent decision reimburses semaglutide (Ozempic) through the National Health Service (SNS). It targets those with inadequately controlled type 2 diabetes, BMI ≥30 kg/m², or high cardiovascular ...
Surge in Obesity Intervention Costs in the Netherlands

By HEOR Staff Writer

Obesity intervention costs in the Netherlands have skyrocketed, with a Zorginstituut Nederland report detailing a €61.8 million rise from 2021 to 2024 ...
Enhancing Patient Safety in Africa’s Healthcare Transformation

By HEOR Staff Writer

February 2, 2026

Prioritizing Patient Safety Africa in 2026 Trends Patient safety Africa stands at the forefront as regulatory bodies drive healthcare self-reliance amid global shifts. A recent article (linked below) outlines five pivotal trends pro...
HPV Vaccination Benefits Portugal: A Cost-Benefit Analysis of Expansion Effects

By João L. Carapinha

What are the HPV vaccination benefits Portugal can expect from expanding coverage? HPV vaccination benefits Portugal by delivering strong economic returns. Extending the National Immunization Program (NIP) to adult males up to age 26 and unvaccinated women aged 18-26 yields benefit-cost ratios (B...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk

By HEOR Staff Writer

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysis of clinical and real-world data, that glucagon-l...
Expansion of Generic Medicines Authorization in Portugal

By João L. Carapinha

928 New Medicines Authorizations Boost Portugal's Health Access In 2025, Portugal's National Authority for Medicines and Health Products (
View All News
Search By Category

Syenza's Top Picks

CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals

2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions

Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential

WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults

Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programme 2026

Preparing for the EU Health Technology Assessment: Key Insights from the Upcoming 2026 Webinar

Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chronic Disease Medications by 2027

Latest

Ozempic Public Funding Approval in Portugal: Key Insights and Implications

By HEOR Staff Writer

February 3, 2026

Ozempic public funding is now approved in Portugal for specific adults with type 2 diabetes. Infarmed's recent decision reimburses semaglutide (Ozempic) through the National Health Service (SNS). It targets those with inadequately controlled type 2 diabetes, BMI ≥30 kg/m², or high cardiovascular ...

Latest

Surge in Obesity Intervention Costs in the Netherlands

By HEOR Staff Writer

Obesity intervention costs in the Netherlands have skyrocketed, with a Zorginstituut Nederland report detailing a €61.8 million rise from 2021 to 2024 ...

Latest

Enhancing Patient Safety in Africa’s Healthcare Transformation

By HEOR Staff Writer

February 2, 2026

Prioritizing Patient Safety Africa in 2026 Trends Patient safety Africa stands at the forefront as regulatory bodies drive healthcare self-reliance amid global shifts. A recent article (linked below) outlines five pivotal trends pro...

Latest

HPV Vaccination Benefits Portugal: A Cost-Benefit Analysis of Expansion Effects

By João L. Carapinha

What are the HPV vaccination benefits Portugal can expect from expanding coverage? HPV vaccination benefits Portugal by delivering strong economic returns. Extending the National Immunization Program (NIP) to adult males up to age 26 and unvaccinated women aged 18-26 yields benefit-cost ratios (B...

Global Updates

Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable Healthcare

By HEOR Staff Writer

January 23, 2026

Sandoz's Strategic Momentum in Biosimilars and Generics Sandoz's biosimilars strategy, as highlighted during the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlines its prog...

Global Updates

Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management

By HEOR Staff Writer

January 21, 2026

Sustained Composite Treatment Targets Enhance Clinical and Economic Outcomes in Type 2 Diabetes A recent modeling study examines the long-term benefits of achieving

Global Updates

Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...

Global Updates

Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards

By João L. Carapinha

January 7, 2026

Aligning U.S. Childhood Immunization Schedules with International Benchmarks Recent childhood immunization reforms by the U.S. Centers for Disease Control and Prevention (CDC) follow a presidential directive...

Europe

View All
Ozempic Public Funding Approval in Portugal: Key Insights and Implications

By HEOR Staff Writer

February 3, 2026

Ozempic public funding is now approved in Portugal for specific adults with type 2 diabetes. Infarmed's recent decision reimburses semaglutide (Ozempic) through the National Health Service (SNS). It targets those with inadequately controlled type 2 diabetes, BMI ≥30 kg/m², or high cardiovascular ...
Surge in Obesity Intervention Costs in the Netherlands

By HEOR Staff Writer

Obesity intervention costs in the Netherlands have skyrocketed, with a Zorginstituut Nederland report detailing a €61.8 million rise from 2021 to 2024 ...
HPV Vaccination Benefits Portugal: A Cost-Benefit Analysis of Expansion Effects

By João L. Carapinha

February 2, 2026

What are the HPV vaccination benefits Portugal can expect from expanding coverage? HPV vaccination benefits Portugal by delivering strong economic returns. Extending the National Immunization Program (NIP) to adult males up to age 26 and unvaccinated women aged 18-26 yields benefit-cost ratios (B...
Expansion of Generic Medicines Authorization in Portugal

By João L. Carapinha

928 New Medicines Authorizations Boost Portugal's Health Access In 2025, Portugal's National Authority for Medicines and Health Products (

North America

View All
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk

By HEOR Staff Writer

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysis of clinical and real-world data, that glucagon-l...
Trump Economic Revival: Key Policies and Impacts from Davos 2026

By João L. Carapinha

January 23, 2026

Trump's Davos 2026 Economic Revival: Claimed Policy Impacts and Metrics In his special address at the World Economic Forum's Annual Meeting 2026 in Davos, Switzerland, U.S. President Donald J. Trump highlighted t...
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children

By João L. Carapinha

January 19, 2026

FDA Labeling Mandate on Febrile Seizure Risks In a significant update to vaccine safety protocols, the U.S. Food and Drug Administration (FDA) has required pediatric influenza vaccines to include warnings about an elevated risk of febri...

Sub-Saharan Africa

View All
Enhancing Patient Safety in Africa’s Healthcare Transformation

By HEOR Staff Writer

February 2, 2026

Prioritizing Patient Safety Africa in 2026 Trends Patient safety Africa stands at the forefront as regulatory bodies drive healthcare self-reliance amid global shifts. A recent article (linked below) outlines five pivotal trends pro...
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...
Driving Economic Transformation through Brain Health Investment in Africa

By João L. Carapinha

January 9, 2026

The Johannesburg Communiqué from the Africa Task Force on Brain Health declares that investing in brain health is crucial, as it supports Africa’s economic transformation and Agenda 2063 goals while covering dementia, mental health, brain trauma, and substance abuse. This investment aligns with N...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity

By João L. Carapinha

January 6, 2026

Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...